Menu Search
Equities

ADR120S Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
3750:TYO

ADR120S Inc

Actions
Real EstateReal Estate Investment and Services
  • Price (JPY)868.00
  • Today's Change-2.00 / -0.23%
  • Shares traded1.50k
  • 1 Year change-4.62%
  • Beta0.3601
Data delayed at least 15 minutes, as of Feb 17 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

ADR120S Inc, formerly Cytori Cell Research Institute Inc, is a Japan-based company mainly engaged in investing in medical assets, buying and selling real estate, investing in real estate business projects, and managing its real estate holdings. The Company operates its business through two segments. The Medical Business segment is engaged in investments in regenerative medicine and other businesses. The Real Assets business segment is mainly engaged in real estate sales and purchase, investment in real estate business projects, and hotel business.

  • Revenue in JPY (TTM)39.92m
  • Net income in JPY-1.71bn
  • Incorporated2004
  • Employees10.00
  • Location
    ADR120S Inc9FFDC Kojimachi Bldg., 2-3-3, Koji-machiCHIYODA-KU 102-0083JapanJPN
  • Phone+81 362619067
  • Fax+81 362619068
  • Websitehttps://adr.co.jp/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		3750:TYO since
announced		Transaction
value
Athletemed CorpAnnounced29 Oct 202529 Oct 2025Announced3.58%--
Data delayed at least 15 minutes, as of Feb 17 2026 06:30 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.